The (cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in COPD patients: the COPE-II study

Tanja Effing1,2, Huib Kerstjens3, Paul Van Der Valk1, Gerhard Zielhuis4, Job Van Der Palen1,5

1 Medisch Spectrum Twente, Department Of Pulmonology, Enschede, The Netherlands
2 Repatriation General Hospital, Department Of Respiratory Medicine, Daw Park, South Australia, Australia
3 University Medical Center Groningen, And University Of Groningen, Department Of Pulmonology, Groningen, The Netherlands
4 Radboud University Nijmegen, Department Of Epidemiology, Biostatistics, And Hta, Nijmegen, The Netherlands
5 Department Of Research Methodology, Measurement And Data Analysis, University Of Twente, Enschede, The Netherlands

Corresponding author
Tanja Effing
Repatriation General Hospital
Department of Respiratory Medicine
Daws Road
Daw Park SA 5041
Australia
Fax: +61 8 8275 1195
Tel: +61 8 8275 1189
E-mail: tanja.effing@health.sa.gov.au

Key words: COPD Exacerbations; Clinical Epidemiology; Health Economist.

“The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its licensees to permit this article (if accepted) to be published in [THORAX] editions and any other BMJPG Ltd products to exploit all subsidiary rights, as set out in our licence (http://thorax.bmj.com/ifora/licence.pdf).
ABSTRACT
COPD is a chronic disease with high prevalence and quickly increasing incidence rates. We evaluated the effect of self-treatment of COPD exacerbations on the severity of exacerbations during one year. In addition, a cost-effectiveness analysis was performed.

Patients were randomly allocated to four two-hour self-management sessions, with or without training in self-treatment of exacerbations. Patients in the self-treatment group received an action plan with the possibility to initiate a prednisolone course (with or without antibiotics). During follow up all participants kept a daily symptom diary. These provided the data to calculate the frequency of exacerbations, the number of exacerbation days and mean daily severity scores.

Data were analysed of 142 randomised patients (self-treatment: n=70; control: n=72). The frequency of exacerbations was identical in both study groups (mean 3.5 (SD 2.7)). Patients in the self-treatment group reported fewer exacerbation days (median self-treatment: 31 (interquartile range (IQR): 8.9-67.5); control: 40 (IQR: 13.3-88.2); p=0.064), the difference was significant in the group of patients with a high number of exacerbation days per year (>137 (= 90th percentile of the whole study population); p=0.028). The mean severity score of an exacerbation day was equal in both groups. No between-group differences were found in health related quality of life. Cost-effectiveness analyses showed that applying self-treatment saved €154 per patient, with a trend towards a lower probability for hospitalisations (number/patient/year: self-treatment: 0.20 versus control: 0.33 (p=0.388)) and a significant reduction of health care contacts (number/patient/year: self-treatment: 5.37 versus control: 6.51 (p=0.043)).

We conclude that self-treatment of exacerbations incorporated in a self-management programme leads to less exacerbation days and lower costs.
INTRODUCTION
The course of chronic obstructive pulmonary disease (COPD) is characterised by episodes of acute deterioration in respiratory health, termed ‘exacerbations’. These exacerbations account for much of the morbidity, mortality, and hospital admissions in COPD patients (1). The majority of all costs in COPD patients are related to the treatment of acute exacerbations, with the costs of hospitalisations being the major component (2).

Patients seem to be capable of identifying warning signs and symptoms of exacerbations (3), but they often do not report an exacerbation to their physician and are therefore potentially delaying treatment (1;4). Proper guidelines for self-treatment of exacerbations might help to induce prompt treatment of exacerbations, thereby accelerating recovery and probably reducing the risk of hospitalisation. Therefore, self-treatment of exacerbations has the potential to reduce their severity and associated costs.

Until today, there is no consensus about the exact definition of a COPD exacerbation let alone its severity. Several frequently quoted definitions of exacerbations are based on respiratory symptoms (1;5), and therefore the number and length of exacerbations can be defined by using daily symptom scores (1). Severity of exacerbations is often characterized by type of health care consumption (e.g., courses of steroids, hospitalisations) (6), but the number of exacerbation days in combination with daily symptom scores as a measure of severity, might be a more precise alternative. Because in most COPD patients the presence of symptoms is more the rule than the exception, using the change in level of symptoms relative to baseline instead of the absolute level could increase the accuracy of the outcome measurement even more (4).

We evaluated the effects of self-treatment of exacerbations within a self-management programme in a randomised study: the COPE-II study. The severity of exacerbations (total number of exacerbation days combined with the average daily severity score) was assessed by determining change relative to baseline in daily symptoms during a one-year follow-up. In addition a cost-effectiveness analysis was performed.

MATERIAL AND METHODS
Patients
From November 2004 through July 2006, 159 patients were recruited from the outpatient department of pulmonary medicine of medisch spectrum twente hospital at enschede, the netherlands. Patients had to meet the following criteria; 1) a clinical diagnosis of COPD according to the GOLD criteria (6); 2) no exacerbation in the month prior to enrolment; 3) ≥ 3 exacerbations, defined as respiratory problems that required a course of oral corticosteroids and/or antibiotics, or ≥ 1 hospitalisation for respiratory problems in the two years preceding study entry; 4) (ex) smoker; 5) age 40-75 years; 6) post-bronchodilator FEV1 25%-80% of predicted; 7) able to understand and read dutch; and 8) written informed consent from the subject prior to participation. Patients were excluded if they had: 1) serious other disease with a low survival rate; 2) other diseases influencing bronchial symptoms and/or lung function (e.g., cardiac insufficiency, sarcoidosis); 3) severe psychiatric illness; 4) uncontrolled diabetes mellitus during a COPD exacerbation in the past or a hospitalisation for diabetes mellitus in the two years preceding the study; 4) need for regular oxygen therapy (> 16 hours per day or po2<7.2 kpa); 5) maintenance therapy with antibiotics; ; 6) known α1-antitrypsine deficiency; 7) disorders or progressive disease seriously influencing walking ability (e.g., amputation, paralysis, progressive muscle disease). The hospital’s medical ethics committee approved the study.
Study design

A two-by-two factorial design was used, meaning that two independent interventions (self-treatment and a community-based physiotherapeutic exercise programme (COPE-active)) were evaluated using one design (table 1). The effect of a self-management programme including self-treatment of exacerbations (self-treatment group) was compared with a self-management programme only (control group). Patients receiving COPE-active were divided equally over the self-treatment and control group using a minimisation program (7), minimising differences between groups in gender, current smoking, FEV1 predicted (≤ or ≥ 50%), and use of inhaled corticosteroids. This design assumes that both interventions do not interact with each other which need to be verified before the final analyses. Measurements of health related quality of life, anxiety and depression, and lung function were performed at baseline, and after 7 and 12 months.

Table 1. Description of the design of the cope-ii study, including the two interventions (self-treatment of exacerbations and cope-active) and the measurements at baseline, 7, and 12 months

<table>
<thead>
<tr>
<th>Time schedule</th>
<th>Interventions</th>
<th>Self-treatment group (=intervention group)</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Subgroup 1</td>
<td>Subgroup 2</td>
</tr>
<tr>
<td>Month 0</td>
<td>Baseline measurement</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Month 1</td>
<td>Self-management courses</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Month 1-12</td>
<td>Self-treatment of exacerbations</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Month 2-7</td>
<td>Cope-active: ‘compulsory’</td>
<td>X</td>
<td>-</td>
</tr>
<tr>
<td>Month 7</td>
<td>Measurement</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Month 8-12</td>
<td>Cope-active: ‘voluntary’</td>
<td>X</td>
<td>-</td>
</tr>
<tr>
<td>Month 12</td>
<td>Measurement</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

Self-management sessions and self-treatment intervention

Smokers were offered a three month smoking cessation program prior to the group-allocation (8). After randomisation, patients of both study groups and their partners were offered four weekly two-hour small-group (approximately 5 patients) self-management sessions given by a respiratory nurse and a physiotherapist. The intention of the courses was to change the patients’ disease behaviour by increasing their knowledge, confronting them with consequences of specific behaviour, and supplying them with tools to deal with different components of their disease. Patients of the intervention group additionally received training in self-treatment of exacerbations. Four, 13, and 26 weeks after the last course, the respiratory nurse contacted all patients by phone to recall the items addressed during the self-management courses. Patients were supplied with a booklet with the content of the courses.

All patients were educated in completing daily diaries, in which they had to report whether their major symptoms (breathlessness, sputum production, sputum colour) and minor symptoms (cough, wheeze, running nose, sore throat, and fever (> 38.5˚C)) according to anthonisen (5) were beyond normal. At inclusion all patients received a ‘what is normal’ card, which described their individual levels of major symptoms in stable health state. When patients experienced no deterioration of any of the symptoms listed on the diary, they could tick ‘no change in symptoms’. In other cases, they had to report on all the symptoms in the diary whether the level of each symptom was normal, slightly increased, or clearly increased.

The start of the exacerbation was defined as ‘a clear negative change in two major
symptoms or one major and one minor symptom from baseline, for at least two consecutive
days’. The day that the exacerbation was resolved was defined as the first day of: 1) three
successive days that the patient had returned to his normal health state; or 2) seven
consecutive days on which patients continuously reported no or only a slight increase in
symptoms compared to baseline, with no fever or change in sputum colour.

Patients in the self-treatment group were educated in early recognition of exacerbations
and were taught when to start a course of oral prednisolone by using an action plan that was
linked to the daily diary. For treatment of an exacerbation, either diagnosed by the physician
or by the patient from the action plan, a course of prednisolone (30 mg for seven days) was
the standard medication. Change of sputum colour was the indicator to combine prednisolone
with antibiotics (amoxicillin/clavulanic acid 500/125 mg [augmentin®] three times daily for a
7 days, or (in case of hypersensitivity) doxycycline 100 mg daily for 10 days.

Patients in the control group were instructed to call the study office if they felt in need
of assistance for any worsening of their respiratory symptoms, which normally would have
prompted them to call their chest physician or general practitioner instead. A consultation
with a chest physician was scheduled within 12 hours.

Outcomes
The total number of exacerbation days was calculated by summing up all exacerbation days
per patient per year, based on the information from the diaries. The severity of an
exacerbation day was calculated with help of symptom scores. The major symptoms were
scored as: normal = 0; small increase = 1; or clear increase = 2. The minor symptoms were
scored 0, 0.5 and 1, respectively. Sputum colour was scored as: normal = 0, different from
normal = 2; and fever: no=0, yes=1. Adding all these scores resulted in a daily score with a
range from 0-11 points. When patients were admitted to the hospital a daily score of 15 points
was assigned. If patients had less than 4 months of complete diary data, they were excluded
from the analyses.

Health related quality of life (HRQoL) was measured with the self-administered
Chronic Respiratory Questionnaire Standardised (CRQ-SAS) (9). The questionnaire captures
four domains: dyspnoea, fatigue, emotional functioning, and mastery. A change of 0.5 in a
domain is considered to be clinically relevant at the individual level (10). Health status was
evaluated by the self-administrated Clinical COPD Questionnaire (CCQ) (11). A change of
0.4 represents the minimal important difference for an individual patient (12). Anxiety and
depression was measured with the Hospital Anxiety and Depression Scale (HADS) (13). This
instrument produces separate scores for anxiety and depression ranging from 0-21. A score
over 10 is judged to be a predictor of a clinical diagnosis of anxiety and depression. Finally,
information about hospital admissions, emergency room visits, scheduled and emergency
outpatients visits, phone calls with physicians, consultations with the general practitioner, and
information about medication use was collected for cost-effectiveness analyses.

Statistical analyses
We calculated that 79 patients per treatment group were required to detect a difference of 2
exacerbation days (SD 4.5 days) with 80% power and a two-sided 0.05 α-level test. All
statistical analyses were performed on an intention-to-treat basis using SPSS version 12.0.
Between-group differences of ‘exacerbation days/year’ and ‘mean severity score/year’ were
assessed by comparing the proportion of patients with an individual value larger than the
median, the 75th, and the 90th percentile. Subsequently chi-square statistics for categorical
variables were applied. Between-group differences of continuous variables were assessed by
analysis of repeated measurements using the SPSS mixed models procedure, and in case of continuous variables (number of hospitalisations, courses of prednisolone / antibiotics) by the student T-test (normal distribution) or the Wilcoxon rank sum test (non-normal distribution). In case of a non-normal distribution, the median combined with the interquartile range (IQR) was presented.

**Cost-effectiveness**

A decision analytical model with a time perspective of 12 months was developed to evaluate the cost effectiveness of a self-management programme including self-treatment of exacerbations versus a self-management programme only. Resource use was multiplied by 2004 unit prices (14). Medication costs were based on market prices and included a €6 dispensing fee and 6% VAT for each prescription. We took the perspective of the health care payer. The costs-effectiveness ratio was calculated as costs per exacerbation day prevented, per hospital admission prevented, and per health care contact prevented.

For sensitivity analysis a Monte Carlo simulation with 1000 iterations was performed to evaluate the relative impact of likely variations in the parameters in the decision analytical model. Therefore, cost parameters and probabilities were varied simultaneously over their ranges and associated 95% CI. For the costs of health care contacts and hospital admissions a normal distribution was used, while for the costs of the self-management programme, exacerbations, and regular medication a triangular distribution was used. Logistic normal distributions were used for all probabilities.

**Results**

Of the 421 eligible patients, 80 were assigned to the self-treatment group and 79 to the control group (figure 1). Between inclusion and the baseline measurements three patients dropped out in each group and insufficient diary data were delivered by 11 patients. Baseline characteristics of the remaining 142 patients are presented in table 2 and were similar between both groups with respect to all measured prognostic factors. The drop outs (n=11) did not differ from the remaining group with respect to all factors, except the medical research council dyspnoea scale (drop outs versus remaining patients: 2.3 (SD 1.1) versus 3.0 (SD 1.1; p=0.041). During the one-year follow-up, three self-treatment group patients dropped out, of which one died due to an intracerebral haemorrhage. Thus, 67 patients in the self-treatment group and 72 patients in the control group completed the one-year follow-up.

**Table 2.** Baseline characteristics of the two treatment groups

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Self-treatment (n=70)</th>
<th>Control (n=72)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean ± sd; years)</td>
<td>63.1 ± 7.9</td>
<td>63.7 ± 8.0</td>
</tr>
<tr>
<td>Male (%)</td>
<td>57.1</td>
<td>61.1</td>
</tr>
<tr>
<td>Smokers (%)</td>
<td>32.9</td>
<td>33.3</td>
</tr>
<tr>
<td>Medical research council dyspnoea scale (mean ± sd)</td>
<td>2.31 ± 1.06</td>
<td>2.33 ± 1.14</td>
</tr>
<tr>
<td>Lung function post bronchodilation (mean ± sd)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 (l)</td>
<td>1.44 ± 0.56</td>
<td>1.41 ± 0.50</td>
</tr>
<tr>
<td>FEV1 % predicted value</td>
<td>50.7 ± 16.3</td>
<td>49.6 ± 15.3</td>
</tr>
<tr>
<td>VC (l)</td>
<td>3.64 ± 1.08</td>
<td>3.66 ± 0.85</td>
</tr>
<tr>
<td>Inhaled corticosteroid use (%)</td>
<td>88.6</td>
<td>84.7</td>
</tr>
</tbody>
</table>
The frequency of exacerbations was the same in both study groups (3.5 (SD 2.7)). Figure 2 shows that patients in the self-treatment group had a lower total number of exacerbation days than patients in the control group. Differences were significant in the group patients with a relatively high number of exacerbation days per year (>137 days/year (=P90 of the whole study population); p=0.028). The mean severity score of an exacerbation day did not differ between both study groups (self-treatment: 5.1 (SD 2.4); control: 5.1 (SD 3.0)). Additional analyses of the more severe exacerbation days (daily score > 6 points, which represents a maximum score on all major symptoms), showed a (non significant) trend towards a higher number of severe exacerbation days/year in the control group (median self-treatment: 11 (IQR: 0.8-21.0); control: 15 (IQR: 3.3-26.8); p=0.124).

The self-reported number of prednisolone (median: self-treatment 2.6 (IQR: 1.0-5.0); control 1.7 (IQR: 1.0-3.2); p=0.055) and antibiotic courses (median: self-treatment 2.0 (IQR: 0.8-4.0); control 1.1 (IQR: 0.0-2.9); p=0.048) were higher in the self-treatment group. The number of hospital admissions was 14 in the STG and 24 in the control group (p=0.388). No between-group differences were found in the CRQ-components, the CCQ (sub)-scores, the HAD scores, and FEV1% of predicted over the 12-month period.

Cost-effectiveness

Table 3 presents the percentages, which are derived from the COPE-II study, for each step in the decision analytic model (figure 3). Figure 3 shows, besides the percentages of patients for each step, also the percentages of patients in the different branches. For example, the percentage of patients in the self-treatment group having at least one exacerbation (90%), one health care contact (100%), and one hospitalisation (17.7%) is 15.9% (90% * 100% * 17.7%). The costs made by a patient in this branch are €6388. These costs consists of: the costs of a self-management course including self-treatment (€118), regular medication costs (€761), health care contacts costs (€281) (table 4), and the hospitalisation costs (€5227). In this branch medication for an exacerbation is incorporated in hospitalisation costs. The percentage of patients in each branch will finally determine the weight of the branch costs to the total costs/patient/study group (e.g., 15.9% * €6388).

| Table 3. Base case values of percentages of patients with a copd exacerbation, a hospitalisation and medication use for an exacerbation |
|---------------------------------------------------------------|---------------------------------|
| Patients with an exacerbation (%)                             | 90.0 (83.1 to 96.9)             |
| Patients with a hospitalisation when having an exacerbation and health care contact (%) | 17.7 (8.8 to 26.6)              |
| Patients with medication use for an exacerbation when not hospitalised but having an exacerbation and a health care contact (%) | 90.8 (84.0 to 97.6)              |
| Patients with a healthcare contact (%)                        | 90.0 (83.1 to 96.9)             |
| Patients with medication use for an exacerbation when not hospitalised but having an exacerbation and a health care contact (%) | 17.7 (8.8 to 26.6)              |
| Patients with medication use for an exacerbation when not hospitalised but having an exacerbation and a health care contact (%) | 90.8 (84.0 to 97.6)              |
Table 4. Mean costs (€) per patient per year in patients with and without self-treatment using 2004 costs prices

<table>
<thead>
<tr>
<th>Costs per patient (€)</th>
<th>Self-treatment (n=70)</th>
<th>Control (n=72)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-management courses</td>
<td>117.68</td>
<td>111.60</td>
<td>6.08</td>
</tr>
<tr>
<td>Regular medication*</td>
<td>761.21</td>
<td>644.00</td>
<td>117.21</td>
</tr>
<tr>
<td>Health care contacts†</td>
<td>262.49</td>
<td>366.70</td>
<td>-104.21</td>
</tr>
<tr>
<td>patients with an exacerbation</td>
<td>280.52 (90%)</td>
<td>402.94 (84.7%)</td>
<td></td>
</tr>
<tr>
<td>patients without an exacerbation</td>
<td>100.21 (10%)</td>
<td>166.07 (15.3%)</td>
<td></td>
</tr>
<tr>
<td>Hospitalisation costs‡</td>
<td>823.24</td>
<td>1020.36</td>
<td>-197.12</td>
</tr>
<tr>
<td>Medication for exacerbations**</td>
<td>75.30</td>
<td>51.40</td>
<td>23.90</td>
</tr>
<tr>
<td>Total costs (€)</td>
<td>2039.92</td>
<td>2194.06</td>
<td>-154.14</td>
</tr>
</tbody>
</table>

* Includes €6 pharmacy cost and 6% vat per prescription
† Includes (telephone) consultations with the physician and general practitioner, and emergency room visits
‡ Costs per hospitalisation day: €337 (includes medication costs); mean of 12.21 and 9.08 hospitalisation days per admission and 14 and 24 admissions for respectively the self-treatment and control group. The sum of €5227 for hospitalisation costs as mentioned in an example in the text are the hospitalisation costs per self-treatment patient having at least one hospitalisation: average costs of a hospitalisation * (total number of hospitalisations in the self-treatment group / total number of intervention patients with > one exacerbation).
** Mean of medically treated exacerbations per patient per year for respectively the self-treatment and control group: treatment with prednisolone and antibiotics: 2.31 versus 1.43 (€ 27.69 per exacerbation); treatment with solely prednisolone: 0.93 versus 0.82 (€7.79 per exacerbation); and treatment with solely antibiotics: 0.21 versus 0.27 (€19.90 per exacerbation)

The 12 month costs data are presented in table 4 and the effect data in table 5. The self-treatment strategy was dominant over the control strategy. Patient in the self-treatment group generated €2040 in direct medical costs versus €2194 in the control group. So, applying self-treatment saved €154 per patient. The number needed to treat (NNT) to prevent one hospitalisation was 7.4, and the NNT to prevent one health care contact was 0.9. The results of the sensitivity analysis with regard to costs for hospital admissions and health care contacts are shown in figure 4 the dominant outcome: a positive treatment effect in combination with saving money was seen in the majority of the outcomes (hospitalisations: 63.3%; health care contacts: 49.2%). Positive effects, independent of costs, were seen in 95.1% and 74.4% of the iterations for hospitalisations and health care contacts, respectively.

Table 5 Effects per patient per year of copd patients receiving a self-management programme with and without self-treatment

<table>
<thead>
<tr>
<th>Effect per patient</th>
<th>Self-treatment (n=70)</th>
<th>Control (n=72)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of exacerbation days</td>
<td>42.20</td>
<td>64.50</td>
<td>-22.30</td>
</tr>
<tr>
<td>Number of hospitalisations</td>
<td>0.200</td>
<td>0.334</td>
<td>-0.134</td>
</tr>
<tr>
<td>Number of health care contacts*</td>
<td>5.373</td>
<td>6.513</td>
<td>-1.140</td>
</tr>
</tbody>
</table>
* Includes (telephone) consultations with the physician and general practitioner, and emergency room visits

**Discussion**

This study showed that self-treatment of exacerbations leads to fewer exacerbation days in combination with an increase in the use of courses of prednisolone and antibiotics. No between-group differences in the number of exacerbations, average daily severity score, and hrQOL were found. Cost-effectiveness analyses showed that the self-treatment strategy was dominant over (i.e. Compared favourably with) the control strategy with lower probabilities for hospitalisations and health care contacts in the self-treatment group, combined with cost savings.

Prior to the study we hypothesised that the severity of exacerbations, defined by the length of the exacerbation in combination with the daily severity scores, would be influenced by the self-treatment guidelines because self-treatment would lead to a more rapid start of treatment after the early recognition of an exacerbation. A priori, we did not expect an effect on exacerbation frequency because self-treatment was initiated after the onset of an exacerbation. Both hypotheses were confirmed by our results. Our study data showed a reduction of the number of exacerbation days in the self-treatment group. Remarkably this was not accompanied by a reduction in the mean daily severity score. A closer look suggests that this lack of difference in daily severity score between both study groups is, at least partly, explained by the fact that self-treatment particularly reduces the number of the less severe exacerbation days (towards the resolution phase of the exacerbation) in the self-treatment group. As a consequence, the average daily severity score (total severity score / number of exacerbation days / patient) of the remaining days of the self-treatment group goes up. We hypothesise that the mean severity score in the control group was higher due to the fact that patients in this group experienced both a higher number of more severe exacerbation days as well as a higher number of less severe exacerbation days. This hypothesis is supported by the (non-significant) trend towards a larger number of more severe exacerbation days (symptom score > 6 points) in the control group.

The difference in severity of exacerbations between both study groups might have been underestimated. By participating in the self-management programme, patients of the control group might have become more aware of the negative consequences of exacerbations and might have contacted the hospital quicker than they were used to. Furthermore, because of their participation in this study, control patients experienced a very low threshold for contacting, and a very short delay in actually being seen by a chest physician (< 12 hours), relative to usual care practice. This all might have led to a more rapid start of treatment and as a consequence a less severe exacerbation.

All patients, so also the control group, received a self-management programme. This increased the costs also in the control group, and raises the question whether a control group without self-management programme would have constituted a clearer design. However, a comparison between our self-treatment group and a control group receiving no intervention at all would probably have led to similar conclusions with regard to cost-effectiveness, since the favourable effects of the intervention would probably have increased further. Furthermore, the costs of the self-management programme (€112) were very low and avoiding them would therefore have saved little.

Similar to other studies (15), including COPE-I (16), our data showed a significantly higher reported use of courses prednisolone and antibiotics in the self-treatment group. But since the number of reported courses in the self-treatment group was still lower than the actual number of exacerbations reported in the diaries, meaning that prednisolone was not used...
during each exacerbation, we are convinced that the between-group difference in courses is
due to a underreporting of respiratory complaints to the chest physician by patients in the
control group, rather than a reflection of overtreatment in the self-treatment group. This
underreporting has also been observed in several other studies (1;3;17).

No effects were found on HRQoL and lung function. Associations between
exacerbation frequency and HRQoL (1;18;19) and between severity of exacerbations and
HRQoL (18) have been demonstrated by others. Since we found no effect on exacerbation
frequency, a relation with changes in hrqol or lung function was no longer expected.

In this study, change from baseline was used to define symptoms and therefore
exacerbation severity. This method was introduced because almost all COPD patients always
experience at least some symptoms in stable state. Using health care consumption (courses of
prednisolone / antibiotics) instead of this change from baseline in symptoms, leads to a lower
number of exacerbations in both study groups. On the other hand, using symptoms from the
diaries, but only as presence or absence (instead of change relative to baseline) would most
likely lead to the detection of more (and more severe) exacerbations. Whether the use of these
other definitions would also affect the estimates of treatment effects remains to be studied.

Using a 2-by-2 factorial design confers the theoretical risk of interaction between both
interventions. A priori, there were no reasons to assume an interaction of a physiotherapeutic
exercise program and self-treatment of exacerbations with regard to the different outcomes.
Since the proportion of patients receiving physiotherapy was the same in both study groups,
possible (additional) effects of the COPE-active program will have affected both study groups
and will thereby not directly influence the between-group differences. Before the final
analysis we have checked for interaction between both interventions and we concluded that
interaction was not present.

The dominance of the self-treatment strategy was largely caused by the lower
probability for hospitalisation in the self-treatment group. As expected, no significant
between-group differences in hospital admissions were found, since this study was not at all
powered to detect a difference in hospital admissions.

In summary, we conclude that self-treatment incorporated in a self-management
programme in COPD patients leads to less exacerbation days at lower costs, while not leading
to overtreatment. Given the rise in prevalence of COPD, and the costs associated with
treatment, we suggest to start implementation programmes incorporating careful instructions
on self-treatment as a part of self-management programmes.

Acknowledgements
We gratefully acknowledge all the members of our department of pulmonary medicine, but
especially the nurse practitioner clara van ommeren, the lung function technician irma
wissink, the data managers betty rinsma and petra meerlo, and of course the patients.

This study was funded by a grant from the dutch asthma foundation.

Disclosure of interests:
The authors te, hk, pv, gz and jp have declared no conflict of interest including involvement
with any organisation with a direct financial, intellectual, or other interest in the subject of the
manuscript (e.g. An author is an employee, consultant, shareholder, or paid expert witness of
the organisation).
Legend Figure 2:
* Chi-square test (< or > 35 (=median of the whole population): p=0.06
† Chi-square test (< or > 69.4 (=p75 of the whole population): p=0.38
‡ Chi-square test (< or > 137.2 (=p90 of the whole population): p=0.03

Reference List


**Figure 1. Flow diagram of subject progress through the COPE-II study**

Eligible patients: n=421
- Excluded: n=262
  - Refused to participate; n=130
  - Participation in other research projects; n=33
  - Transport problems; n=22
  - Other reasons; n=77

Randomisation
- Self-treatment group: n=80
  - Withdrawn: n=3
    - Co-morbidity; n=1
    - Too busy; n=2
  - Insufficient diary data: n=7
    - Not motivated; n=6
    - Not capable; n=1

- Control group: n=79
  - Withdrawn: n=3
    - Co-morbidity; n=2
    - Too busy; n=1
  - Insufficient diary data: n=4
    - Not motivated; n=2
    - Died (not enough data); n=2

Baseline measurement: n=70
- Withdrawn: n=3
  - Failure to return; n=2
  - Death; n=1

One-year follow-up: n=67

Baseline measurement: n=72
- Withdrawn: n=4
  - Not motived; n=4

One-year follow-up: n=72
Figure 2. Number of exacerbation days per year for patients in the intervention and control group; median, 75th and 90th percentile of both study groups and the corresponding p-values for group differences are also reflected.

- Intervention group (n=70)
  - Median: 31
  - P75: 67.5
  - P90: 111.9

- Control group (n=72)
  - Median: 40 *
  - P75: 88.3 †
  - P90: 196.9 ‡

* Chi-Square test (≤ or > 35 (=median of the whole population): p=0.06
† Chi-Square test (≤ or > 69.4 (=p75 of the whole population): p=0.38
‡ Chi-Square test (≤ or > 137.2 (=p90 of the whole population): p=0.03
Figure 3. Decision analytic model with percentages of patients with exacerbations, health care contacts, hospitalisations and medication for exacerbations for the self-treatment and control group.
Figure 4. Results of the sensitivity analysis (1000 iterations) on cost per hospital admission prevented and cost per health care contact prevented. A negative € amount and a positive difference in the hospitalisations and health care contacts favours the self-treatment intervention. In addition the percentages of outcomes in every quadrant are given.
The (cost)-effectiveness of self-treatment of exacerbations on the severity of exacerbations in COPD patients: the COPE-II study

Tanja W Effing, Huib A M Kerstjens, Paul D L P M van der Valk, Gerhard A Zielhuis and Job van der Palen

Thorax published online September 6, 2009

Updated information and services can be found at:
http://thorax.bmj.com/content/early/2009/09/06/thx.2008.112243

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: infectious diseases (968)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/